Test Directory

Clear All
Test Code
2170
Test Name
Neu-Laxova Syndrome 2
CPT Codes
81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.
Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours
Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
NLS; NLS2
Description

Neu-Laxova syndrome (NLS) is an autosomal recessive disorder characterized by severe congenital malformations leading to prenatal or early postnatal lethality. Main findings include intrauterine growth retardation, microcephaly, ichthyosis, flexion deformities, edema of the hands and feet, and abnormal facial features including abnormal or absent eyelids, flat or abnormal nose, and a round gaping mouth. NLS1 (MIM 256520) and NLS2 (MIM 616038) are caused by mutations in the PHGDH and PSAT1 genes.  They code for D-3-phosphoglycerate dehydrogenase and phosphoserine aminotransferase enzymes, respectively. These enzymes are involved in L-serine biosynthesis. Phosphoglycerate dehydrogenase deficiency (PHGDHD; MIM 601815) and phosphoserine aminotransferase deficiency (PSATD; MIM 610992) are autosomal recessive disorders allelic to more severe disorders, NLS1 and NLS2. PHGDHD and PSATD are characterized by congenital microcephaly, hypertonia, psychomotor retardation and seizures.
Testing Schedule
Monday-Friday
Genes
PSAT1
MIM
616038
Disease Group
Craniosynostosis and Craniofacial Disorders, Hair and Nail disorders, Neuromuscular, Skin
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.